The prevalence of hypertension remains high in hemodialysis (HD) patients, leading to a considerable morbimortality. The “dry weight method (DW),” established by Scribner, presents an undeniable interest in the management of hypertension in HD patients. Aim. The aim of our work was to determine the prevalence and risk factors (RFs) of hypertension in our chronic HD patients and try to reduce it by using a therapeutic education (TE) strategy based on Scribner’s recommendations. Patients and Methods. We led an interventional prospective study in three phases. In phase 1, we determined the prevalence of hypertension. In phase 2, hypertensive patients benefited of a TE strategy. In phase 3, we evaluated the effects of our TE. Results. Hypertension was noted in 57 patients. RFs for hypertension included age, important interdialytic weight gain (IDWG), noncompliance to the dietary rules, and a rhythm of 2 sessions of dialysis per week. The use of a TE strategy enabled us to correct hypertension in some of our HD patients. Conclusion. A TE strategy improved the hypertension rate in our HD unit. This success could not be conceived without an educational effort supported by the whole medical team. 1. Introduction The prevalence of hypertension remains high in hemodialysis (HD) patients, leading to a considerable morbimortality, and an unsatisfactory quality of life. The “dry weight method (DW),” established by Scribner, presents an undeniable interest in the management of hypertension in HD patients [1]. It is based on a gradual reduction of dry weight (DW), respect of sodium balance during the dialysis session, performance of sufficiently long dialysis sessions, a low sodium diet, and the gradual withdrawal of antihypertensive drugs [1]. Our study was conducted in three stages, each with distinct objectives. The aim in the first stage was to determine the prevalence of hypertension and its risk factors within our population of chronic hemodialysis patients. Then, in the second stage, we aimed to lower the blood pressure levels of our patients by adopting a therapeutic education (TE) strategy based on Scribner’s recommendations. Finally, we evaluated the effects of our nonpharmacological treatment and our educational involvement. 2. Patients and Methods Our interventional prospective study was carried out in three months, from October to December 2011, and in three stages. It enrolled 93 chronic hemodialysis patients from our hemodialysis unit. The first stage consisted of an assessment of the epidemiological context, a determination of the prevalence of
References
[1]
B. H. Scribner, R. Buri, J. E. Caner, R. Hegstrom, and J. M. Burnell, “The treatment of chronic uremia by means of intermittent hemodialysis: a preliminary report,” Transactions—American Society for Artificial Internal Organs, vol. 6, pp. 114–122, 1960.
[2]
A. Giordan, “Therapeutic patient education: the main learning models which underlie them,” Medecine des Maladies Metaboliques, vol. 4, no. 3, pp. 305–311, 2010.
[3]
P. Simon, “Epidémiologie de l'HTA en dialyse,” Néphrologie & Thérapeutique, vol. 3, pp. S143–S149, 2007.
[4]
C. M. Kjellstrand, A. A. Rosa, J. R. Shideman, F. Rodrigo, T. Davin, and R. E. Lynch, “Optimal dialysis frequency and duration: the ‘unphysiology hypothesis’,” Kidney International, Supplement, no. 8, pp. S120–S124, 1978.
[5]
R. M. Fagugli, G. Reboldi, G. Quintaliani, et al., “Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients,” American Journal of Kidney Diseases, vol. 38, pp. 371–376, 2001.
[6]
P. Simon, S. Benarbia, C. Charasse et al., “Ischemic renal diseases have become the most frequent causes of end stage renal disease in the elderly,” Archives des Maladies du Coeur et des Vaisseaux, vol. 91, no. 8, pp. 1065–1068, 1998.
[7]
E. Ritz, “Lowering of blood pressure—The lower, the better?” Journal of the American Society of Nephrology, vol. 17, no. 9, pp. 2345–2352, 2006.
[8]
B. Charra and C. Chazot, “Volume control, blood pressure and cardiovascular function: lessons from hemodialysis treatment,” Nephron Physiology, vol. 93, no. 4, pp. p94–p101, 2003.
[9]
P. J. Conlon, J. J. Walshe, S. K. Heinle, S. Minda, M. Krucoff, and S. J. Schwab, “Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients,” Journal of the American Society of Nephrology, vol. 7, no. 12, pp. 2658–2663, 1996.
[10]
R. N. Foley, P. S. Parfrey, and M. J. Sarnak, “Epidemiology of cardiovascular disease in chronic renal disease,” Journal of the American Society of Nephrology, vol. 9, no. 12, pp. S16–23, 1998.
[11]
G. M. London and T. B. Drüeke, “Atherosclerosis and arteriosclerosis in chronic renal failure,” Kidney International, vol. 51, pp. 1678–1695, 1997.
[12]
G. M. London, A. P. Guérin, S. J. Marchais et al., “Cardiac and arterial interactions in end-stage renal disease,” Kidney International, vol. 50, no. 2, pp. 600–608, 1996.
[13]
D. M. Lloyd-Jones, J. C. Evans, M. G. Larson, C. J. O'Donnell, E. J. Roccella, and D. Levy, “Differential control of systolic and diastolic blood pressure factors associated with lack of blood pressure control in the community,” Hypertension, vol. 36, no. 4, pp. 594–599, 2000.
[14]
G. M. London, S. J. Marchais, A. P. Guérin, and F. Métivier, “Blood pressure control in chronic hemodialysis patients,” in Replacement of Renal Function by Dialysis, W. H. H？rl, K. M. Koch, R. M. Lindsay, C. Ronco, and J. F. Winchester, Eds., pp. 741–764, Kluwer Academic, Dordrecht, The Netherlands, 2004.
[15]
E. Ritz, R. Dikow, C. Morath, and V. Schwenger, “Salt—a potential 'uremic toxin'?” Blood Purification, vol. 24, no. 1, pp. 63–66, 2006.
[16]
A. C. Guyton, T. G. Coleman, and H. J. Granger, “Circulation: overall regulation,” Annual Review of Physiology, vol. 34, pp. 13–46, 1972.
[17]
K. E. Kim, G. Onesti, A. B. Schwartz, J. L. Chinitz, and C. Swartz, “Hemodynamics of hypertension in chronic end-stage renal disease,” Circulation, vol. 46, no. 3, pp. 456–464, 1972.
[18]
N. Fujiwara, T. Osanai, T. Kamada, T. Katoh, K. Takahashi, and K. Okumura, “Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake,” Circulation, vol. 101, no. 8, pp. 856–861, 2000.
[19]
T. Osanai, N. Fujiwara, M. Saitoh et al., “Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease,” Blood Purification, vol. 20, no. 5, pp. 466–468, 2002.
[20]
K. S. Katzarski, B. Charra, A. J. Luik et al., “Fluid state and blood pressure control in patients treated with long and short haemodialysis,” Nephrology Dialysis Transplantation, vol. 14, no. 2, pp. 369–375, 1999.
[21]
G. E. Thomson, K. Waterhouse, H. P. McDonald Jr., and E. A. Friedman, “Hemodialysis for chronic renal failure. Clinical observations,” Archives of Internal Medicine, vol. 120, no. 2, pp. 153–167, 1967.
[22]
C. R. V. Tomson, “Advising dialysis patients to restrict fluid intake without restricting sodium intake is not based on evidence and is a waste of time,” Nephrology Dialysis Transplantation, vol. 16, no. 8, pp. 1538–1542, 2001.
[23]
C. Chazot and B. Charra, “Non pharmacologic treatment of hypertension in hemodialysis patients,” Néphrologie & Thérapeutique, vol. 3, pp. S178–S184, 2007.
[24]
U. M. Khosla and R. J. Johnson, “Hypertension in the hemodialysis patient and the “lag phenomenon”: insights into pathophysiology and clinical management,” American Journal of Kidney Diseases, vol. 43, no. 4, pp. 739–751, 2004.
[25]
S. Shaldon, “An explanation for the “lag phenomenon” in drug-free control of hypertension by dietary salt restriction in patients with chronic kidney disease on hemodialysis,” Clinical Nephrology, vol. 66, no. 1, pp. 1–2, 2006.
[26]
P. Blanc, “Therapeutic education or the dynamics of learning,” éthique et Santé, vol. 6, pp. 92–96, 2009.
[27]
B. Sandrin-Berthon, “Pourquoi parler d’éducation dans le champ de la médecine?” in L'éducation du Patient au Secours de la Médecine, pp. 8–39, 2000.
[28]
C. Saout, B. Charbonnel, and B. Bertrand, Pour une politique nationale d'éducation thérapeutique du patient. Rapport remis au ministre de la santé, de la jeunesse et des sports et de la vie associative, 2008.
[29]
P. G. Gibson, H. Powell, J. Coughlan et al., “Self-management education and regular practitioner review for adults with asthma,” Cochrane Database of Systematic Reviews, no. 1, p. CD001117, 2003.
[30]
Y. Magar, D. Vervloet, F. Steenhouwer et al., “Assessment of a therapeutic education programme for asthma patients: ‘Un souffle nouveau’,” Patient Education and Counseling, vol. 58, no. 1, pp. 41–46, 2005.
[31]
D. Vervloet, “éducation thérapeutique: école de l'asthme: Réseaux, école de l'asthme: Où en est-on?” 15e CPLF. Lille, 28–31 janvier 2011.
[32]
D. Ausubel, J. Novak, and H. Hanesian, Educational Psychology: A Cognitive View, Holt, Rinehart & Winston, New York, NY, USA, 2nd edition, 1978.
[33]
J. Piaget, Psychologie et Pédagogie. Gonthiers Deno？l, Collection Médiations, 1969.
[34]
J. Piaget, La psychologie de l’intelligence, Armand Colin, Paris, Farnce, 9 edition, 1967.
[35]
A. Giordan, Apprendre ! Paris: Belin, Collection Débats, 2002.
